{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:53:49Z","timestamp":1769072029229,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To determine the application of fluorescein angiographic (FA) findings and Behcet\u2019s disease ocular attack score 24 (BOS24) scoring system in predicting poor visual outcome in patients with ocular Behcet\u2019s disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Study design<\/jats:title>\n                <jats:p>Retrospective cohort study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We included 73 eyes of 38 patients with ocular Behcet\u2019s disease who underwent FA and reviewed FA images, anterior chamber cells, vitreous opacity, retinal and optic disc lesions, which are parameters in BOS24. The correlation between FA findings, BOS24, and visual acuity was assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Optic disc hyperfluoresence (74%), diffuse posterior pole leakage (52%) and diffuse peripheral leakage (52%) were the three most common findings. Common complications were peripheral capillary nonperfusion (29%), arterial narrowing (22%), and macular ischemia (19%). BOS24 scores of\u2009\u2265\u20096 (p\u2009&lt;\u20090.0001), arterial narrowing (p\u2009&lt;\u20090.0001), and severe posterior pole leakage (p\u2009=\u20090.004) were significantly associated with poor visual outcome. Combining significant FA findings: arterial narrowing and severe posterior pole leakage, to BOS24\u2009\u2265\u20096 results in an increased relative risk of developing poor visual acuity from 7.30 to 10.43 and 1.89 to 2.02 respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Fluorescein angiography is an important investigation for predicting poor visual outcome. BOS24 may be a useful alternative when fluorescein angiographic is unavailable.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40942-021-00318-4","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T12:02:54Z","timestamp":1630152174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Fluorescein angiographic findings and Behcet's disease ocular attack score 24 (BOS24) as prognostic factors for visual outcome in patients with ocular Behcet's disease"],"prefix":"10.1186","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7937-7406","authenticated-orcid":false,"given":"Narumon","family":"Keorochana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathamon","family":"Homchampa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sritatath","family":"Vongkulsiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raveewan","family":"Choontanom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,28]]},"reference":[{"key":"318_CR1","unstructured":"Posarelli C, Maglionico MN, Talarico R, Covello G, Figus M. Beh\u00e7et's syndrome and ocular involvement: changes over time; Clin Exp Rheumatol. 2020;38 Suppl 127(5):86\u201393"},{"issue":"2","key":"318_CR2","first-page":"15","volume":"20","author":"H Chams","year":"2008","unstructured":"Chams H, et al. The risk factors and causes for blindness in Behcet\u2019s disease. J Iranian J Ophthalmol. 2008;20(2):15\u20139.","journal-title":"J Iranian J Ophthalmol."},{"issue":"6","key":"318_CR3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3109\/09273948.2012.713159","volume":"20","author":"AK Cingu","year":"2012","unstructured":"Cingu AK, et al. Comparison of presenting features and three-year disease course in Turkish patients with Beh\u00e7et uveitis who presented in the early 1990s and the early 2000s. Ocul Immunol Inflamm. 2012;20(6):423\u20138.","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"318_CR4","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.ajo.2008.06.019","volume":"146","author":"RO Ka\u00e7maz","year":"2008","unstructured":"Ka\u00e7maz RO, et al. Ocular inflammation in Beh\u00e7et\u2019s disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol. 2008;146(6):828\u201336.","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"318_CR5","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1136\/bjo.70.8.589","volume":"70","author":"D Benezra","year":"1986","unstructured":"Benezra D, Cohen E. Treatment and visual prognosis in Beh\u00e7et\u2019s disease. Br J Ophthalmol. 1986;70(8):589\u201392.","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"318_CR6","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1136\/bjo.2007.123554","volume":"91","author":"N Kitaichi","year":"2007","unstructured":"Kitaichi N, et al. Ocular features of Beh\u00e7et\u2019s disease: an international collaborative study. Br J Ophthalmol. 2007;91(12):1579.","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"318_CR7","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.ajo.2011.05.032","volume":"152","author":"SRJ Taylor","year":"2011","unstructured":"Taylor SRJ, et al. Beh\u00e7et disease: visual prognosis and factors influencing the development of visual loss. Am J Ophthalmol. 2011;152(6):1059\u201366.","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"318_CR8","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1007\/s00417-017-3667-0","volume":"255","author":"R Amer","year":"2017","unstructured":"Amer R, et al. Pattern and causes of visual loss in Beh\u00e7et\u2019s uveitis: short-term and long-term outcomes. Graefe\u2019s Arch Clin Exp Ophthalmol. 2017;255(7):1423\u201332.","journal-title":"Graefe's Arch Clin Exp Ophthalmol"},{"key":"318_CR9","doi-asserted-by":"publisher","first-page":"R99","DOI":"10.1186\/ar3824","volume":"143","author":"S Sugita","year":"2012","unstructured":"Sugita S, et al. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Beh\u00e7et\u2019s disease. Arthritis Res Ther. 2012;143:R99\u2013R99.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"318_CR10","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1136\/bjophthalmol-2012-302515","volume":"97","author":"T Sakai","year":"2013","unstructured":"Sakai T, et al. Health- and vision-related quality of life in patients receiving infliximab therapy for Beh\u00e7et uveitis. Br J Ophthalmol. 2013;97(3):338.","journal-title":"Br J Ophthalmol"},{"key":"318_CR11","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/sj.eye.6702352","volume":"21","author":"B Mushtaq","year":"2006","unstructured":"Mushtaq B, et al. Adalimumab for sight-threatening uveitis in Beh\u00e7et\u2019s disease. Eye. 2006;21:824.","journal-title":"Eye"},{"issue":"3","key":"318_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10384-006-0425-y","volume":"51","author":"M Accorinti","year":"2007","unstructured":"Accorinti M, et al. Infliximab treatment for ocular and extraocular manifestations of Beh\u00e7et\u2019s disease. Jpn J Ophthalmol. 2007;51(3):191\u20136.","journal-title":"Jpn J Ophthalmol"},{"issue":"3","key":"318_CR13","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/BOR.0000000000000497","volume":"30","author":"F Alibaz-Oner","year":"2018","unstructured":"Alibaz-Oner F, Sawalha AH, Direskeneli H. Management of Beh\u00e7et\u2019s disease. Curr Opin Rheumatol. 2018;30(3):238\u201342.","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"318_CR14","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","volume":"121","author":"G Levy-Clarke","year":"2014","unstructured":"Levy-Clarke G, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(3):785-796.e3.","journal-title":"Ophthalmology"},{"issue":"13","key":"318_CR15","first-page":"5128","volume":"48","author":"S Lee","year":"2007","unstructured":"Lee S, et al. Visual prognosis and risk factors for Korean patients with Behcet uveitis. Invest Ophthalmol Vis Sci. 2007;48(13):5128\u20135128.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"318_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2021.03.001","author":"M Lin","year":"2021","unstructured":"Lin M, Anesi SD, Chang PY, Eggenschwiler L, Manhapra A, Walsh M, Foster CS. Clinical features, visual outcome, and poor prognostic factors in occlusive retinal vasculitis. Can J Ophthalmol. 2021. https:\/\/doi.org\/10.1016\/j.jcjo.2021.03.001.","journal-title":"Can J Ophthalmol."},{"issue":"4","key":"318_CR17","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3349\/ymj.2015.56.4.1087","volume":"56","author":"M Kim","year":"2015","unstructured":"Kim M, et al. Correlation between fluorescein angiographic findings and visual acuity in Beh\u00c3\u00a7et retinal vasculitis. Yonsei Med J. 2015;56(4):1087\u201396.","journal-title":"Yonsei Med J"},{"issue":"1","key":"318_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/09273940490518757","volume":"13","author":"\u015e Gedik","year":"2005","unstructured":"Gedik \u015e, et al. Indocyanine green and fundus fluorescein angiographic findings in patients with active ocular Beh\u00e7et\u2019s disease. Ocul Immunol Inflamm. 2005;13(1):51\u20138.","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"318_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/09273940802553279","volume":"17","author":"HG Yu","year":"2009","unstructured":"Yu HG, Kim MJ, Oh FS. Fluorescein angiography and visual acuity in active uveitis with Beh\u00e7et disease. Ocul Immunol Inflamm. 2009;17(1):41\u20136.","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"318_CR20","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1080\/08820538.2016.1178310","volume":"32","author":"F Bazvand","year":"2017","unstructured":"Bazvand F, et al. Ocular manifestations, conventional fundus fluorescein angiographic findings, and relationship between angiographic findings and visual acuity in Beh\u00e7et\u2019s Disease. Semin Ophthalmol. 2017;32(6):764\u201371.","journal-title":"Semin Ophthalmol"},{"issue":"2","key":"318_CR21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s10384-013-0294-0","volume":"58","author":"T Kaburaki","year":"2014","unstructured":"Kaburaki T, Namba K, Sonoda KH, et al. Behcet\u2019s disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of inflix- imab. Jpn J Ophthalmol. 2014;58(2):120\u201330.","journal-title":"Jpn J Ophthalmol"},{"key":"318_CR22","doi-asserted-by":"crossref","unstructured":"Tanaka R, et al. Beh\u00e7et's disease ocular attack score 24 and visual outcome in patients with Beh\u00e7et's disease, vol 100. 2015.","DOI":"10.1136\/bjophthalmol-2015-307362"},{"issue":"2","key":"318_CR23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/25785826.2020.1800244","volume":"44","author":"H Keino","year":"2021","unstructured":"Keino H. Evaluation of disease activity in uveoretinitis associated with Beh\u00e7et\u2019s disease. Immunol Med. 2021;44(2):86\u201397. https:\/\/doi.org\/10.1080\/25785826.2020.1800244 (Epub 2020 Jul 29).","journal-title":"Immunol Med"},{"issue":"3","key":"318_CR24","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/jdv.12107","volume":"28","author":"F Davatchi","year":"2014","unstructured":"Davatchi F, et al. The International Criteria for Beh\u00e7et\u2019s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338\u201347.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"318_CR25","first-page":"539","volume":"30","author":"I Tugal-Tutkun","year":"2010","unstructured":"Tugal-Tutkun I, et al. Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis). Int Opthamol. 2010;30(5):539\u201352.","journal-title":"Int Opthamol."},{"issue":"3","key":"318_CR26","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","volume":"138","author":"I Tugal-Tutkun","year":"2004","unstructured":"Tugal-Tutkun I, et al. Uveitis in Beh\u00e7et disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373\u201380.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"318_CR27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s10384-013-0294-0","volume":"58","author":"T Kaburaki","year":"2014","unstructured":"Kaburaki T, et al. Beh\u00e7et\u2019s disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab. Jpn J Ophthalmol. 2014;58(2):120\u201330.","journal-title":"Jpn J Ophthalmol"},{"issue":"11","key":"318_CR28","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00417-005-0005-8","volume":"243","author":"M Takeuchi","year":"2005","unstructured":"Takeuchi M, et al. Risk and prognostic factors of poor visual outcome in Behcet\u2019s disease with ocular involvement. Graefes Arch Clin Exp Ophthalmol. 2005;243(11):1147\u201352.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"318_CR29","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S0161-6420(87)33314-7","volume":"94","author":"RB Nussenblatt","year":"1987","unstructured":"Nussenblatt RB, et al. Macular thickening and visual acuity: measurement in patients with cystoid macular edema. Ophthalmology. 1987;94(9):1134\u20139.","journal-title":"Ophthalmology"},{"issue":"1\u20132","key":"318_CR30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.joco.2015.10.003","volume":"27","author":"H Chams","year":"2015","unstructured":"Chams H, et al. Ophthalmic findings in Behcet\u05f3s disease: cases without apparent ocular signs. J Curr Ophthalmol. 2015;27(1\u20132):46\u201350.","journal-title":"J Curr Ophthalmol"},{"issue":"6","key":"318_CR31","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/09273940591004232","volume":"13","author":"JK Ahn","year":"2005","unstructured":"Ahn JK, Chung H, Yu HG. Vitrectomy for persistent panuveitis in Beh\u00e7et\u2019s disease. Ocul Immunol Inflamm. 2005;13(6):447\u201353.","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"318_CR32","first-page":"256","volume":"50","author":"I Tugal-Tutkun","year":"2006","unstructured":"Tugal-Tutkun I, et al. Neovascularization of the optic disc in Beh\u00e7et\u2019s disease. Japan J Ophthamol. 2006;50(3):256\u201365.","journal-title":"Japan J Ophthamol"},{"issue":"3","key":"318_CR33","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0002-9394(14)77719-0","volume":"85","author":"P Henkind","year":"1978","unstructured":"Henkind P. Ocular neovascularization: the krill memorial lecture. Am J Ophthalmol. 1978;85(3):287\u2013301.","journal-title":"Am J Ophthalmol"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-021-00318-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-021-00318-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-021-00318-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T12:14:33Z","timestamp":1630152873000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-021-00318-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,28]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["318"],"URL":"https:\/\/doi.org\/10.1186\/s40942-021-00318-4","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,28]]},"assertion":[{"value":"22 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work involving human data were under the ethical standards of the institutional and national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. It was approved by the Institutional Review Board, Royal Thai Army Medical Department. Patient consent was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SV reports personal fees from Novartis and personal fees from Bayer. The other authors declare that they have no completing of interest in this work. All authors attest that they meet the current ICMJE criteria for Authorship.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}